Leadership Overview
Emcure has 5 executives leading key functions including strategy, finance, and operations.
Driven by a commitment to scientific advancement, Emcure is dedicated to delivering innovative and affordable medicines that address a wide spectrum of medical conditions and therapeutic needs across the global healthcare sector.
Driven by a commitment to scientific advancement, Emcure is dedicated to delivering innovative and affordable medicines that address a wide spectrum of medical conditions and therapeutic needs across the global healthcare sector.
Leadership Roles at Emcure
Satish Mehta - Chief Executive Officer
Satish Mehta, the Chief Executive Officer at Emcure, directs the overall strategic vision and operational execution for the global pharmaceutical enterprise. Overseeing all facets of the organization, the Chief Executive Officer ensures alignment with Emcure's mission to research, develop, manufacture, and market a broad range of pharmaceutical products and healthcare solutions. This leadership role involves driving innovation and scientific advancement to formulate medicines that address unmet medical needs and improve patient outcomes. By focusing on complex generics, biosimilars, and specialized formulations, Satish Mehta guides the company's efforts to continuously introduce improved therapies and drug delivery systems. The Chief Executive Officer's strategic direction is critical for enhancing treatment effectiveness and patient safety across domestic and global healthcare markets. Ultimately, Satish Mehta secures Emcure's position as a research-focused leader in the pharmaceutical industry.
Tajuddin Shaikh - Group Chief Financial Officer
Tajuddin Shaikh, the Group Chief Financial Officer at Emcure, manages all financial operations and fiscal strategy for the international pharmaceutical enterprise. Overseeing global financial planning, budgeting, and reporting, the Group Chief Financial Officer ensures the fiscal health and sustainability of Emcure's diverse operations. This critical role involves managing capital allocation, optimizing financial performance, and driving revenue growth in alignment with the company's research-focused strategy. Tajuddin Shaikh's financial acumen supports the development and marketing of innovative and affordable medicines across domestic and global healthcare markets. By ensuring robust financial controls and strategic investments, the Group Chief Financial Officer facilitates Emcure's expansion into areas like complex generics and biosimilars. Ultimately, Tajuddin Shaikh's leadership ensures the financial resources are effectively deployed to advance scientific discovery and improve patient outcomes worldwide.
Rohit Pant - President
Rohit Pant, the President at Emcure, drives key strategic initiatives and operational excellence across the global pharmaceutical company. Overseeing significant business units, the President ensures the seamless execution of Emcure's mission to deliver innovative and affordable healthcare solutions. This leadership position involves fostering cross-functional collaboration to advance research, development, and marketing efforts for a broad range of pharmaceutical products. Rohit Pant's focus on scientific advancement supports the formulation of medicines addressing unmet medical needs and enhancing patient outcomes. By championing operational efficiencies, the President contributes to Emcure's strong presence in both domestic and global healthcare markets. The President's strategic oversight is vital for the successful introduction of complex generics, biosimilars, and specialized pharmaceutical formulations. Ultimately, Rohit Pant's leadership ensures Emcure's commitment to improving treatment effectiveness and patient safety.
Kuber Jagdale - President
Kuber Jagdale, the President at Emcure, spearheads critical operational functions and strategic growth areas for the global pharmaceutical enterprise. Overseeing specific divisions, the President ensures the effective implementation of Emcure's strategy to research, develop, and market a wide array of pharmaceutical products and healthcare solutions. This role emphasizes driving scientific advancement and innovation to create affordable medicines that address diverse medical conditions. Kuber Jagdale's leadership supports the company's focus on complex generics, biosimilars, and biologics, contributing to improved patient outcomes. By managing key operational aspects, the President strengthens Emcure's international presence and its commitment to delivering high-quality therapies. The President's strategic guidance is essential for enhancing treatment effectiveness and patient safety across global markets. Ultimately, Kuber Jagdale ensures Emcure's continued success in addressing unmet medical needs.
Vikas Thapar - President, Corporate Development, Strategy & Finance
Vikas Thapar, the President, Corporate Development, Strategy & Finance at Emcure, architects the company's long-term strategic planning and financial architecture. Overseeing corporate development initiatives, mergers, acquisitions, and financial strategy, the President, Corporate Development, Strategy & Finance ensures Emcure's sustainable growth and market expansion. This pivotal role involves identifying strategic opportunities, managing financial resources, and aligning fiscal operations with the company's research-focused mission. Vikas Thapar's expertise is crucial for driving innovation and the development of affordable medicines that address a broad spectrum of medical conditions. By guiding strategic investments and financial frameworks, the President, Corporate Development, Strategy & Finance supports Emcure's strong domestic and global healthcare market presence. The President, Corporate Development, Strategy & Finance's leadership is instrumental in advancing complex generics, biosimilars, and specialized pharmaceutical formulations. Ultimately, Vikas Thapar secures Emcure's financial stability and strategic positioning for future success.
Explore Leadership Teams in Manufacturing
Founded in 1891 and headquartered in Rahway, NJ, Merck & Co., Inc. is a global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
Company Leadership NM
RS
GO
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence in countries such as the United States, Japan, China, and the United Kingdom. The company maintains a significant focus on research and development in the pharmaceutical sector, with particular emphasis on patient-centered healthcare solutions. Eisai's business model encompasses both business-to-business and business-to-consumer operations, reflecting its comprehensive approach to healthcare delivery and pharmaceutical development.
Company Leadership
SG
YF
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Company Leadership EL
SG
JB
CJ
LTS Lohmann Therapie-Systeme AG is a pharmaceutical technology company that specializes in developing and manufacturing advanced drug delivery systems for the global healthcare industry. The company focuses on innovative ways to administer medicines through the skin, mouth, and other non-invasive routes, enabling more effective, patient-friendly, and controlled therapies. Its core expertise lies in technologies such as transdermal patches that deliver drugs through the skin, oral thin films that dissolve quickly in the mouth for rapid absorption, and microarray patch systems that use microscopic structures to deliver active ingredients into the skin in a minimally invasive manner. LTS also develops wearable injection devices and topical patch systems designed to improve convenience, adherence, and treatment outcomes for patients with chronic and complex medical conditions. The company operates as a contract development and manufacturing partner for pharmaceutical organizations, supporting the entire lifecycle of drug delivery solutions from early-stage development and formulation to large-scale production and commercialization. By combining scientific research, engineering capabilities, and industrial manufacturing, LTS enables its partners to bring new therapies to market more efficiently while improving patient experience and compliance. Its technologies are used in a wide range of therapeutic areas, including pain management, neurological disorders, hormone therapies, and other chronic conditions that require sustained or controlled drug release. With a global presence across Europe, North America, and Asia, LTS maintains production facilities, research centers, and commercial operations that support international pharmaceutical partners. The company emphasizes innovation, quality, and regulatory compliance, and continuously invests in new delivery technologies such as microneedle systems and wearable drug delivery platforms to expand future treatment possibilities. Through its integrated approach, LTS ...
Company Leadership AY
SS
Frequently Asked Questions Regarding Emcure Top Executives and Leadership Team
